02 Jun ABC-CT CS
This is a multicenter longitudinal study that aims to validate a set of measures that were previously identified as promising candidate biomarkers and/or sensitive and reliable objective measures of social function in ASD for potential use in clinical trials. The confirmation study will repeat the data collection and analysis protocols from the original ABC-CT study.
The goal of this consortium is to establish tools that can be used as biomarkers and/or sensitive and reliable objective assays of social function in autism spectrum disorder (ASD) clinical trials. Specifically, we aim to accelerate the development of effective treatments for social function in ASD by validating (a) outcome measures that will be sensitive and reliable assessments of response to treatment
and (b) biomarkers in the domains of electroencephalography (EEG), eye-tracking (ET) and behavioral measures of social function to reduce heterogeneity of samples via stratification.
Children will be assessed across three time points (T1: Baseline, T2: 6 weeks, T3: 24 weeks) using clinician and caregiver assessments along with a battery of conceptually related EEG and ET tasks and independent ratings of clinical status.
Children between 6 and 11 years – who have been diagnosed with autism spectrum disorder
Children between 6 and 11 years – who are typically developing and no siblings with ASD
Additional Study Details
Full Study Title
Autism Biomarkers Consortium for Clinical Trials: Confirmation Study
Accepts Healthy Volunteers?
University of Washington
1701 NE Columbia Rd
Seattle, Washington 98195